Osteoarthritis Competitive Landscape 2025: Over 100 Companies Driving a Robust Pipeline of 110+ Emerging Therapies, estimates DelveInsight

DelveInsight's latest analysis reveals that the global Osteoarthritis (OA) pipeline includes more than 100 companies actively developing 110+ therapeutic candidates, spanning diverse clinical stages. The comprehensive evaluation covers clinical trials, therapeutic classes, mechanisms of action, routes of administration, and ongoing R&D developments.

DelveInsight's report, "Osteoarthritis Pipeline Insight, 2025," delivers an in-depth overview of the current clinical landscape and future growth opportunities across the global Osteoarthritis market. The study offers extensive commercial and clinical insights, profiling investigational and marketed products from preclinical research through late-stage development. This includes detailed information on mechanisms of action, clinical progress, regulatory milestones (including NDAs), and product development activities involving technologies, partnerships, mergers and acquisitions, funding rounds, designations, and more.

Request a Sample Report: https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Osteoarthritis Pipeline Report
• Numerous global pharmaceutical and biotech companies are advancing innovative Osteoarthritis treatment options, achieving steady progress over recent years.
• Major companies contributing to the OA treatment landscape include Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A., Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, and several others.
• Key emerging therapies such as Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC-001, among others, are anticipated to significantly influence the Osteoarthritis market in the near future.

Recent Regulatory & Clinical Developments in Osteoarthritis (2023-2025)
• May 2025: Hyalex Orthopaedics received FDA approval for a supplemental IDE, enabling the expansion of its Early Feasibility Study into a pivotal trial for the Freestyle Knee Implant, a next-generation solution designed for patients with cartilage damage and early OA.
• March 2025: Lipogems completed patient enrollment in the ARISE II FDA IDE study evaluating MicroFat injections vs. saline for knee OA. Results are expected in late 2025.
• February 2025: Zydus Lifesciences (NSE: ZYDUSLIFE) obtained final FDA approval for Ibuprofen and Famotidine tablets (Duexis) for rheumatoid arthritis and osteoarthritis-related symptoms.
• February 2025: Aurora Pharmaceutical introduced EquiCoxib, an FDA-approved generic version of Equioxx® (firocoxib), targeting OA-related pain and inflammation.
• January 2025: NEXTBIOMEDICAL CO., LTD received FDA IDE approval for the "RESORB" trial of Nexsphere-FTM, a fast-resorbable embolic microsphere for knee osteoarthritis pain.
• November 2024: Genascence Corporation's GNSC-001 secured Fast Track Designation for knee OA from the FDA.
• December 2023: Bioventus entered into a nationwide agreement with Aetna Medicare Advantage plans, increasing DUROLANE access for millions of members.
• December 2023: Levicept completed recruitment for its Phase II trial of LEVI-04, with topline results expected in mid-2024.
• January 2023: OliPass Corporation initiated a study evaluating the safety and efficacy of OLP-1002 SC injections for moderate to severe hip and knee OA pain.

Get a Free Sample PDF Report to know more about Osteoarthritis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoarthritis: Overview
Osteoarthritis is a degenerative joint disorder marked by progressive cartilage breakdown, joint pain, stiffness, and limited mobility. Osteoarthritis Symptoms commonly include swelling, tenderness, reduced range of motion, and audible crepitus. Disease contributors include aging, genetics, obesity, repetitive joint stress, and previous injuries.

Osteoarthritis Diagnosis relies on clinical examinations, medical history, and imaging tools such as X-rays and MRI. Current management strategies include lifestyle adjustments, physiotherapy, NSAIDs, analgesics, intra-articular therapies, and surgical options like joint replacement for advanced cases. Research continues to focus on disease-modifying therapies, regenerative approaches, and biologics aimed at slowing or reversing disease progression.

Download a Free Sample PDF: https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoarthritis Pipeline Breakdown by Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Osteoarthritis Pipeline Categorization by Molecule Type
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

Osteoarthritis Pipeline Assessment Includes:
• Classification by product type, development stage, route of administration, and molecule type
• Evaluation of late-stage (Phase III), mid-stage (Phase II), early-stage (Phase I), preclinical, and discontinued candidates
• Detailed insights into target receptors, mechanisms of action, monotherapy/combination strategies, and more
• Analysis of collaborations, licensing activities, partnerships, and funding developments

Further Osteoarthritis product details are provided in the report. Download the Osteoarthritis pipeline report to learn more about the emerging Osteoarthritis therapies- https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Osteoarthritis Pipeline Report
• Coverage: Global
• Osteoarthritis Companies: Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A., Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, and others
• Osteoarthritis Emerging Therapies: Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC-001, and more
• Assessment Areas: Marketed & emerging therapies, market drivers and barriers, unmet needs, and future outlook

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading life sciences consulting and market intelligence firm offering end-to-end solutions to pharmaceutical and biotech companies. The organization specializes in market analysis, competitive intelligence, pipeline assessment, and strategic consulting, helping clients drive growth and navigate evolving industry challenges.

This release was published on openPR.